Astellas Stock Replacement Program Eligibility Requirements
In order for the healthcare provider or facility to receive no-cost stock replacement of Astellas medications through the Astellas Stock Replacement Program, the treated patient must satisfy the following criteria:
- Be uninsured
- Have a verifiable shipping address in the United States
- Have been prescribed Mycamine® (micafungin sodium) for injection, for an FDA-approved indication
- Meet the program financial eligibility requirementsa
- Have had Mycamine administered in a healthcare facilityb
Upon completion and submission of the Astellas Stock Replacement Program Application via Astellas eService, we will evaluate whether the patient meets the program criteria.
a Astellas Stock Replacement Program requires the healthcare professional or facility to retain proof of patient income on file in their office.
b Under the Astellas Stock Replacement Program, a healthcare facility may include a physician's office, clinic, hospital inpatient or outpatient department, long-term care facility, or infusion center. It is required under this program that the healthcare provider or an authorized employee at the treating facility certify that the facility is a) under no legal obligation under any federal, state, or local law or regulation to provide a patient with product, and b) will not be receiving a payment for a service that would otherwise fund the provision of the product to the patient (eg, a capitated or bundled payment for an inpatient hospital admission) and also certifies that the facility will waive charges for the administration of product from patients without any health insurance that satisfy all other eligibility criteria.